Lantern Pharma is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Co.'s portfolio of therapies consists of small molecules drug candidates that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with the assistance of its A.I. platform and its biomarker driven approach. The LTRN stock yearly return is shown above.
The yearly return on the LTRN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LTRN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|